Heart failure with preserved ejection fraction — the form of heart failure where the heart pumps normally but fills poorly — has long resisted effective treatment, partly because its root mechanisms span metabolic dysfunction, mitochondrial failure, and gut-derived lipotoxicity simultaneously. A compound found in pomegranates and certain berries, and produced by gut bacteria, may address several of these pathways at once, raising new questions about how the microbiome influences cardiac fate.
Urolithin A (UA) was tested in a dual-insult mouse model of HFpEF induced by high-fat feeding combined with a nitric oxide synthase inhibitor — an established approach to mimic the metabolic and hypertensive stress seen in human HFpEF. UA administration during disease progression significantly attenuated diastolic dysfunction, cardiac hypertrophy, and myocardial fibrosis. Mechanistically, UA activated the energy-sensing kinase AMPK while suppressing mTOR, collectively driving ULK1-dependent initiation of mitophagy — the selective clearance of damaged mitochondria. Mitochondrial ultrastructure was restored, and both mitochondrial respiration and glycolytic capacity improved. Simultaneously, multi-omics profiling showed that UA remodeled the gut microbiome and reduced circulating ceramide levels, curtailing the lipotoxic stress that drives cardiac stiffening. Single-nucleus transcriptomics further indicated that UA dampened fibrosis-related gene programs in human-derived cardiac cells.
This study is notable for integrating several layers of mechanistic evidence — pharmacological, transcriptomic, and metabolomic — into a coherent dual-pathway model: mitophagy restoration plus gut-ceramide axis modulation. However, critical limitations temper enthusiasm. The findings are entirely preclinical; the mouse HFpEF model approximates but does not fully replicate the human syndrome, which is heterogeneous and comorbidity-laden. UA bioavailability varies enormously between individuals based on gut microbiome composition, meaning human trials face significant pharmacokinetic complexity. Prior phase I safety data on UA exist, and early human studies on muscle function are underway, but cardiac endpoints in humans remain untested. This work is directionally significant — HFpEF has few mechanistic therapies — but should be read as hypothesis-generating rather than practice-informing.